Ginette 35: Comprehensive Hormonal Therapy for PCOS and Acne
| Product dosage: 2.035mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 42 | $1.62 | $67.94 (0%) | 🛒 Add to cart |
| 63 | $1.52 | $101.91 $95.46 (6%) | 🛒 Add to cart |
| 84 | $1.45 | $135.88 $122.12 (10%) | 🛒 Add to cart |
| 126 | $1.41 | $203.82 $178.02 (13%) | 🛒 Add to cart |
| 168 | $1.38
Best per pill | $271.76 $231.34 (15%) | 🛒 Add to cart |
Synonyms | |||
Ginette 35 is a combined oral contraceptive and antiandrogen medication, widely prescribed for the management of polycystic ovary syndrome (PCOS) and moderate to severe acne in women. It contains a balanced formulation of cyproterone acetate and ethinylestradiol, which work synergistically to suppress androgen activity and regulate menstrual cycles. This product is indicated for patients requiring both contraceptive protection and dermatological or endocrine benefits, under strict medical supervision.
Features
- Contains 2 mg cyproterone acetate and 0.035 mg ethinylestradiol per tablet
- 21 active tablets per blister pack, with or without 7 placebo tablets
- Oral administration, once daily
- Requires prescription and medical oversight
- Manufactured under GMP standards
Benefits
- Effectively reduces sebum production and improves moderate to severe acne
- Regulates menstrual cycles and reduces symptoms of hyperandrogenism in PCOS
- Provides reliable contraception with a Pearl Index of approximately 0.1-0.9
- Decreases hirsutism and androgen-related alopecia
- May improve lipid profiles in certain patient populations
- Offers predictable withdrawal bleeding and cycle control
Common use
Ginette 35 is primarily prescribed for:
- Treatment of moderate to severe acne related to androgen sensitivity in women
- Management of polycystic ovary syndrome symptoms including hirsutism, seborrhea, and menstrual irregularities
- Hormonal contraception in women requiring antiandrogenic effects
- Off-label uses may include gender-affirming hormone therapy under specialist guidance
Dosage and direction
Take one tablet daily at approximately the same time each day for 21 consecutive days, followed by a 7-day tablet-free interval. During the tablet-free interval, withdrawal bleeding usually occurs. Start the next pack on the 8th day regardless of bleeding status. For first-time users, begin on day 1 of menstrual cycle. If switching from other hormonal contraceptives, consult specific conversion guidelines. Take with water, with or without food.
Precautions
- Regular monitoring of blood pressure, liver function, and metabolic parameters recommended
- Increased risk of venous thromboembolism; discontinue 4 weeks before major surgery
- May affect glucose tolerance; monitor diabetic patients closely
- Caution in patients with history of depression; mood changes may occur
- Reduced efficacy with body mass index >30 kg/m²
- Not recommended for smokers over age 35
Contraindications
- History of or current thrombophlebitis or thromboembolic disorders
- Known or suspected estrogen-dependent neoplasia
- Undiagnosed abnormal genital bleeding
- Known or suspected pregnancy
- Severe hepatic disease or liver tumors
- Hypersensitivity to any component
- Classic migraine with focal neurological symptoms
Possible side effects
Common (≥1/100):
- Headache
- Nausea
- Breast tenderness
- Mood changes
- Breakthrough bleeding
Uncommon (≥1/1000):
- Weight changes
- Libido changes
- Chloasma
- Contact lens intolerance
Rare but serious:
- Venous thromboembolism
- Hepatic adenomas
- Hypertension
- Gallbladder disease
Drug interaction
- Antibiotics (rifampicin, griseofulvin) may reduce efficacy
- Anticonvulsants (carbamazepine, phenytoin) increase metabolism
- HIV protease inhibitors affect cytochrome P450
- St. John’s Wort reduces plasma concentrations
- Cyclosporine levels may increase
- Laboratory test interference with thyroid and adrenal function tests
Missed dose
If less than 12 hours late: Take tablet immediately and continue schedule. If more than 12 hours late:
- Week 1: Use additional contraception for 7 days
- Week 2: Continue normally if previous 7 days taken correctly
- Week 3: Finish active tablets and start new pack immediately (omit placebo week)
- If multiple tablets missed, consult healthcare provider
Overdose
No specific antidote exists. Symptoms may include nausea, vomiting, and withdrawal bleeding. Gastric lavage may be considered if recent ingestion. Symptomatic treatment is recommended. Monitor for electrolyte imbalances in cases of significant overdose.
Storage
Store below 25°C in original packaging. Protect from light and moisture. Keep out of reach of children. Do not use after expiration date. Do not flush medications down toilet or drain.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Ginette 35 requires prescription and medical supervision. Individual response may vary. Always consult qualified healthcare providers for diagnosis and treatment recommendations. Not all possible uses, interactions, or precautions are listed here.
Reviews
Clinical studies demonstrate 70-90% improvement in acne lesions after 6 cycles of treatment. Patients with PCOS show significant reduction in hirsutism scores and improved cycle regularity. Long-term safety data support use for up to 2 years continuously for acne treatment. Real-world evidence indicates high patient satisfaction with dermatological outcomes when used as directed under medical supervision.